Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Aeterna Zentaris Inc (AEZS)

Toronto
Currency in CAD
Disclaimer
2.910
+0.080(+2.83%)
Closed

AEZS Comments

Next week is the expected week
I don't know what is really going on with stock
2 USD by the end of the year
I hope!
I hope!
Sale una nueva variante y no veas la k se lía
why is this 🚀?
There is hype on new COVID treatment announcement and it is/was oversold
Seeing a lot of predictions for 3.50 in the next few days
why?
let's get that oral vaccine out
Than ?
It's spelled -ess h eye tee-
I used to be an enthusiastic bag holder too,...,woke up,dumped the ****
https://www.handelsblatt.com/dpa/wirtschaft-handel-und-finanzen-verband-corona-impfstoffe-zweiter-generation-vielleicht-schon-2021/27222440.html?ticket=ST-5153637-HIXgEEndEVksGk2n6CrC-ap2
https://www.zentaris.com/oral-coronavirus-vaccine
I want to dump my position of this garbage as soon as possible. Been holding since right after the run up in Feb., got in low, but, I don't care. They could have a PR that announced they found a cure for both aging and cancer, and their share price would still be ********
Financials are not favorable, but for some reason I'm considering a risk on this one.
use a real name, ****
awesome quarter
It managed to outperform the Markets overall today, if we are willing to accept sideways as an outperform.
well done aezs
Rename it "Sideways International Inc."
fantastic company
Preclinical trials will likely be completed first. AEZS would then identify the Lead Candidate. An new drug application (IND) would then likely be submitted to the FDA. Once the IND is approved, then Phase 1 trials should begin. When the IND is submitted, the company should announce this to shareholders. Once the IND is approved, this should also be announced to shareholders.
I think the company will go through Germany's FDA and not the USA one
Probably both as US & EU has friendly relations. The thing is, they need to speed up a bit to normalized the global pandemic.
Any thoughts on when the Covid application was submitted. I assume at the same time Aezs signed the license agreement with the uni. Typical response from the gov. Agency for trials is around two months. That puts us around middle of May. Please intelligent comments.
The next VXRT...........Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer
https://www.eurekalert.org/pub_releases/2021-04/uow-cdf042721.php
https://www.eurekalert.org/pub_releases/2021-04/uow-cdf042721.php
I agree 100%
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.